Market Updates

Swift Diagnosis of Heart Attacks with High-Sensitivity Troponin Test

October, 2018

Heart attack is the cause of more than 114,023 lives in US in 2015. Nearly 8 million emergency room visits are recorded in US annually, but only 5.5% are diagnosed with conditions such as heart attack, rupture of aorta, lung embolisms, collapse of lungs, and esophageal ruptures. Equipped with data to eliminate myocardial infarctions, Siemens Healthineers has developed a troponin I assay (TnIH) with high sensitivity for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers for initial diagnosis of myocardial infractions.

This novel test can reduce the total time required for the diagnosis of lethal heart attacks in the patients. On the arrival of an individual with the chest pain to the emergency department, this test helps the physician to confirm the condition in time as less as 10 minutes by determining the presence of the troponin. Troponin is a protein present in cardiac and skeletal muscles and when the heart muscles are injured, it produces troponin into the stream of blood. The level of troponin raises within 3-4 hours since the damage of the heart and can continue to be at a high level for nearly 14 days.

The company claims that the high-sensitivity performance TnIH assays offers the capability to sense lesser levels of troponin at suggestively enhanced the accuracy by 99%, and perceive slighter fluctuations in the level of troponin when the test is repeated. This strategy provides greater assurance in the results for the clinicians due to its high accuracy.

The chief of clinical chemistry and toxicology at Zuckerberg San Francisco General Hospital and Trauma Center, Dr. Alan Wu, stated that “Our emergency department is overcrowded with patients. If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system,”.

The product received its US FDA approval in July 2017, and is launched at the 70th AACC Annual Scientific Meeting and Clinical Lab Expo in Chicago.

- Rikitha K Murthy,
Research Analyst,
Infoholic Research